December 6, 2004 - Bristol Investment Group Raises $1.83 million for SinoFresh Healthcare, Inc.

NEW YORK- Bristol Investment Group, a leading merchant banking firm for growing public and private companies, announced today it has closed on a Convertible Debt financing of $1.83 million for SinoFresh Healthcare (SFSH-OTC BB). Bristol completed the raise with several NYC-based institutions. The financing will provide SinoFresh with additional working capital.

SinoFresh, based in Englewood, Florida, is a developer and marketer of innovative therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company’s lead product, SinoFresh™ Nasal, Oral, and Sinus Care is available nationwide in such stores as Wal-Mart, Walgreens, Rite Aid, and CVS.

“We are pleased to bring additional growth capital into SinoFresh. We believe that consumers are just beginning to understand the power and value of the Company’s product”, said Alan Donenfeld, President of Bristol Investment Group.

About Bristol Investment Group, Inc.

Bristol Investment Group, Inc. is focused on serving the needs of health care, technology and other companies who require growth capital, strategic planning and merger and acquisition advice. The members of the firm have a broad range of experience in raising debt and equity capital, structuring and financing acquisitions, arranging joint ventures and managing communication companies. Mr. Alan Donenfeld, President of Bristol, formed the company in 1990 with the mission of providing a high standard of investment banking services to small and middle market communication companies. Bristol is a broker/dealer firm registered with the National Association of Securities Dealers (NASD) and is member of the Securities Investor Protection Corporation (SIPC). For more information on Bristol Investment Group visit www.BristolDirect.com website.

Back To Press Releases >>>